This circRNA-based gene therapy is proposed to induce the resolution of hepatic steatosis and lipid peroxidation in NAFLD patients via an impact on circRNA_0046367/miR-34a/PPARα axis. The gene discussed is PPARA; the disease is fatty liver disease.